DUETACT Drug Patent Profile

Which patents cover Duetact, and when can generic versions of Duetact launch?

Duetact is a drug marketed by Takeda Pharms Usa and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has fifty-nine patent family members in thirty-one countries.

The generic ingredient in DUETACT is glimepiride; pioglitazone hydrochloride. There are sixteen drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the glimepiride; pioglitazone hydrochloride profile page.

DrugPatentWatch^® Generic Entry Outlook for Duetact

There is one Paragraph IV patent challenge for this drug. This may lead to patent invalidation or a license for generic production.

Indicators of Generic Entry

Summary for DUETACT

International Patents:	59
US Patents:	2
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	142
Drug Prices:	Drug price information for DUETACT
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for DUETACT
What excipients (inactive ingredients) are in DUETACT?	DUETACT excipients list
DailyMed Link:	DUETACT at DailyMed

See drug prices for DUETACT

Pharmacology for DUETACT

Drug Class	Peroxisome Proliferator Receptor alpha Agonist Peroxisome Proliferator Receptor gamma Agonist Sulfonylurea Thiazolidinedione
Mechanism of Action	Peroxisome Proliferator-activated Receptor alpha Agonists Peroxisome Proliferator-activated Receptor gamma Agonists

Paragraph IV (Patent) Challenges for DUETACT

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
DUETACT	Tablets	glimepiride; pioglitazone hydrochloride	30 mg/2 mg and 30 mg/4 mg	021925	1	2009-12-22

US Patents and Regulatory Information for DUETACT

DUETACT is protected by two US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Takeda Pharms Usa	DUETACT	glimepiride; pioglitazone hydrochloride	TABLET;ORAL	021925-001	Jul 28, 2006	AB	RX	Yes	Yes	8,071,130		Y
Takeda Pharms Usa	DUETACT	glimepiride; pioglitazone hydrochloride	TABLET;ORAL	021925-002	Jul 28, 2006	AB	RX	Yes	No	7,700,128		Y
Takeda Pharms Usa	DUETACT	glimepiride; pioglitazone hydrochloride	TABLET;ORAL	021925-001	Jul 28, 2006	AB	RX	Yes	Yes	7,700,128		Y
Takeda Pharms Usa	DUETACT	glimepiride; pioglitazone hydrochloride	TABLET;ORAL	021925-002	Jul 28, 2006	AB	RX	Yes	No	8,071,130		Y

Expired US Patents for DUETACT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Takeda Pharms Usa	DUETACT	glimepiride; pioglitazone hydrochloride	TABLET;ORAL	021925-002	Jul 28, 2006	6,150,383
Takeda Pharms Usa	DUETACT	glimepiride; pioglitazone hydrochloride	TABLET;ORAL	021925-001	Jul 28, 2006	7,538,125
Takeda Pharms Usa	DUETACT	glimepiride; pioglitazone hydrochloride	TABLET;ORAL	021925-001	Jul 28, 2006	4,687,777
Takeda Pharms Usa	DUETACT	glimepiride; pioglitazone hydrochloride	TABLET;ORAL	021925-002	Jul 28, 2006	6,303,640
Takeda Pharms Usa	DUETACT	glimepiride; pioglitazone hydrochloride	TABLET;ORAL	021925-002	Jul 28, 2006	4,687,777
Takeda Pharms Usa	DUETACT	glimepiride; pioglitazone hydrochloride	TABLET;ORAL	021925-001	Jul 28, 2006	6,211,205
Takeda Pharms Usa	DUETACT	glimepiride; pioglitazone hydrochloride	TABLET;ORAL	021925-001	Jul 28, 2006	6,329,404

International Patents for DUETACT

See the table below for patents covering DUETACT around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	240698	PROCEDIMIENTO PARA PREPARAR COMPUESTOS DE 5-(4-(2-(5-ETIL-2-PIRIDIL)-ETOXI)BENZIL)-2,4-TIAZOLIDINDIONA Y SUS SALES (PROCESS FOR THE PREPARATION OF 5-(4-(2-(5-ETHYL-2-PYRIDIL)-ETHOXY)BENZYL)-2,4-THIAZOLODINEDIONE AND THEIR SALTS)
Austria	41931
Australia	5246786
Australia	572719
Brazil	1100325
Canada	1277323	DERIVES DE THIAZOLIDINEDIONE, LEUR PRODUCTION ET LEUR EMPLOI (THIAZOLIDINEDIONE DERIVATIVES, THEIR PRODUCTION AND USE)
China	1003934

Supplementary Protection Certificates for DUETACT

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0861666	91298	Luxembourg		91298, EXPIRES: 20210620
0861666	300258	Netherlands		300258, 20160620, EXPIRES: 20210619
0861666	SPC 038/2006	Ireland		SPC 038/2006: 20070528, EXPIRES: 20210619
0861666	07C0006	France		PRODUCT NAME: PIOGLITAZONE/METFORMINE ET LEURS SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE IN FRANCE: EU/1/06/354/001 DU 20060728; REGISTRATION NO/DATE AT EEC: EU/1/06/354/001 DU 20060728
0861666	CA 2007 00001	Denmark
0861666	SPC/GB07/009	United Kingdom		SPC/GB07/009: 20070126
0861666	C00861666/01	Switzerland		FORMER REPRESENTATIVE: BOHEST AG, CH

Last updated: July 26, 2026

DUETACT (pioglitazone oral) market dynamics and financial trajectory: sales trends, competition, and exclusivity-driven pricing

DUETACT is the brand of fixed-dose combination pioglitazone + glimepiride (oral). In the US, its market position is shaped by (1) ongoing generic pressure on pioglitazone/glimepiride backbones, (2) payer step edits that steer patients toward lower-cost preferred agents, (3) class-level demand shifts toward GLP-1 receptor agonists and SGLT2 inhibitors, and (4) the remaining durability of combination-brand differentiation in segments where fixed-dose adherence matters. Financial trajectory since the mid-2010s has tracked a typical pattern for branded combination products whose core components face broad generic availability.

Core points for business planning

• DUETACT’s addressable population is constrained by the number of patients who start and remain on a pioglitazone + sulfonylurea regimen rather than switching to newer add-on classes.
• Volume is sensitive to payer preference changes because generic monotherapy and generic combinations of its components are widely available.
• Long-term brand value depends more on real-world adherence and low-switching cohorts than on patent-driven exclusivity in later years (when generic entry is already established).

---

What drives DUETACT sales: payer placement, adherence, and diabetes drug class substitution?

DUETACT sits in the intersection of:

• TZD (thiazolidinedione) demand for insulin sensitivity (pioglitazone)
• SULF (sulfonylurea) demand for insulin secretion (glimepiride)

Market dynamics typically move DUETACT with the same drivers that move TZD/SULF overall, but the fixed-dose combination adds adherence and inertia effects.

Payer and formulary dynamics

The strongest near-to-mid-term demand drivers are not clinical endpoints alone but formulary design:

• Step therapy for second-line diabetes often favors agents with superior payer value frameworks (GLP-1 RA, SGLT2 inhibitors), pushing TZD/SULF combinations to later lines.
• Therapeutic interchange is common: if payers cover generic pioglitazone and generic glimepiride with low copays, fixed-dose branding is harder to justify.
• Coverage volatility increases when payers adjust cost-sharing for sulfonylureas due to hypoglycemia risk policies and utilization management.

Practical consequence: DUETACT’s market tends to hold up better than pure TZDs in some formularies because combination dosing can reduce pill burden, but generic backfills usually cap premium pricing.

Adherence and persistence

Fixed-dose products can win where:

• clinicians prefer a single prescription for titration,
• patients prefer fewer tablets,
• plan design reduces refill friction.

This effect narrows as clinicians and payers move to once-weekly injectables or oral SGLT2/GLP-1 regimens that improve A1c outcomes and cardiorenal outcomes used in payer medical policy.

---

How has DUETACT performed financially: revenue trajectory and brand value drivers?

DUETACT is best treated as a mature, off-patent combination brand whose financial trajectory follows category compression.

Expected financial shape for DUETACT

The typical pattern for products like DUETACT after broad generic availability:

1. Peak-to-decline phase driven by generic substitution of pioglitazone and glimepiride.
2. Stabilization pockets where plan tiers and persistence keep volume from collapsing completely.
3. Steeper decline when category substitution accelerates toward GLP-1 RA and SGLT2 inhibitors, and when combination-brand premiums cannot be sustained.

What to watch in quarterly trend interpretation

• Prescription volume growth is usually limited; revenue often tracks net price and rebates more than utilization.
• Loss of formulary status or tighter prior authorization for TZD/SULF regimens causes quicker revenue drops than pure market competition.
• Mix shift: DUETACT may show smaller decline than component monotherapies in specific geographies or plan segments, but overall category demand is pressured.

---

DUETACT vs generic pioglitazone and glimepiride: how does fixed-dose competition affect pricing power?

DUETACT’s commercial economics are dominated by the spread between:

• branded fixed-dose combination pricing (subject to rebate and payer negotiation), and
• generic monotherapy and generic combination pricing for pioglitazone + glimepiride equivalents.

Price elasticity and net-to-gross

Because patients can reach the same active ingredients through generics:

• DUETACT’s price power is capped by copay differentials.
• rebate structures become a battlefield: net price often compresses as payers secure generic coverage.

Formulary design advantage of generics

Even when payers prefer combination dosing for adherence, they often:

• prefer generic equivalents
• use copay assistance for branded injectables and newer classes, not for DUETACT.

Result: DUETACT behaves like a “lifecycle brand” more than a high-growth product.

---

Which diabetes drugs displace DUETACT most: GLP-1, SGLT2, and DPP-4 substitution impacts?

Clinical substitution translates into payer substitution.

GLP-1 receptor agonists

• Often favored for weight loss and A1c outcomes.
• Used earlier in treatment algorithms in many formularies.

SGLT2 inhibitors

• Often favored for cardiorenal outcomes even when A1c targets are met.
• Payers can justify these options using broader endpoints.

DPP-4 inhibitors

• Some payer segments keep them as tolerability alternatives.
• They can displace TZD/SULF in add-on sequences.

Net effect for DUETACT: As clinician selection moves toward GLP-1 RA/SGLT2 earlier, DUETACT faces reduced new patient starts, leaving only those already on TZD/SULF regimens or those who cannot tolerate newer agents.

---

What exclusivity and patent posture matter for DUETACT’s financial ceiling?

For market dynamics, the key is whether any meaningful exclusivity or patent protection blocks generic competition.

Practical market implication

Once a product’s combination is broadly genericized or otherwise easy to replicate therapeutically, future revenue becomes constrained by:

• generic substitution,
• payer preference, and
• diminishing differentiation beyond adherence.

Commercial takeaway: even if residual IP exists for specific formulation, packaging, or methods, the main economic driver is whether generic equivalents can supply the same labeled dosing regimen at lower cost.

---

What is the Orange Book status of DUETACT and what does it mean for generic entry risk?

For an off-patent combination brand, Orange Book listings typically translate into:

• expired or near-expired patents for active ingredient and combination,
• potential remaining patent protection for specific dosing strengths or methods.

Market relevance: if multiple Orange Book patents are already expired, Paragraph IV leverage becomes less relevant for long-horizon revenue. If fewer patents remain, generics can still enter through alternative carve-outs if they are not blocked.

Business use: treat DUETACT’s generic-entry risk as primarily realized rather than a future shock, with ongoing price compression as the continuing threat.

---

How many DUETACT competitors exist: brand vs generic and therapeutic class rivals?

DUETACT competes in two layers.

Layer 1: active-ingredient equivalents

• Generic pioglitazone and generic glimepiride used as separate prescriptions
• Potential generic fixed combinations where available

Layer 2: therapeutic class substitution

• GLP-1 RA
• SGLT2 inhibitors
• DPP-4 inhibitors and other add-on oral agents

Commercial reality: even if generic fixed-dose equivalents are not perfectly identical, therapeutic substitution can capture most displacing demand.

---

Which companies hold DUETACT-like market share: manufacturing and distribution landscape?

The branded DUETACT commercial footprint generally sits with the original brand holder and major diabetes generic manufacturers distributed through pharmacy benefit managers and wholesalers. The more critical competitive axis for financial trajectory is not who manufactures a branded product but who dominates generic access and PBM formulary tiering.

Business implications

• Revenue trajectory depends on PBM contracting and bid outcomes.
• Generic competition is the baseline; differentiation is negotiated, not structural.

---

What does DUETACT mean for investors: downside drivers and upside levers?

Downside drivers

• Continued growth of GLP-1 RA and SGLT2 categories reduces remaining TAM within TZD/SULF pathways.
• PBM cost management pressures fixed-dose brands once copay gaps widen.
• Potential further formulary downgrades in high-utilization plan designs.

Upside levers

• Improving payer coverage through outcomes-based or adherence-based contracting.
• Targeting subpopulations with strong persistence or who remain on TZD/SULF because of contraindications, intolerance, or affordability constraints.

Investment framing: DUETACT is not a platform growth story; it is a value-preservation story dependent on formulary placement and net pricing.

---

Key Takeaways

• DUETACT’s market dynamics are dominated by generic equivalence of its active ingredients and payer step edits that increasingly favor newer diabetes classes.
• Its financial trajectory has followed the lifecycle pattern of a mature, off-patent combination brand: decline with stabilization pockets, followed by further pressure as GLP-1 RA/SGLT2 uptake rises.
• Competitive threats are layered: direct cost competition from generics and indirect displacement from GLP-1 RA/SGLT2 earlier-in-therapy strategies.
• Near-term revenue preservation depends more on formulary access, rebate structure, and persistence than on novel clinical differentiation.

---

FAQs

Is DUETACT used mainly as second-line therapy or add-on therapy?

It is typically positioned as an add-on regimen when monotherapy does not achieve control, with payer protocols often determining exact sequencing.

Do GLP-1 RA and SGLT2 inhibitors reduce DUETACT demand?

Yes. As formularies favor GLP-1 RA and SGLT2 earlier in treatment, TZD/SULF combinations see reduced new starts.

Can DUETACT maintain pricing despite generic pioglitazone and glimepiride?

Net pricing is usually compressed by PBM leverage; any premium depends on negotiated rebates and formulary tier placement.

What happens to DUETACT volume when formularies tighten copays for older diabetes classes?

Volume usually declines faster once patient cost-sharing and prior authorization requirements make access harder.

Is DUETACT’s long-term risk mainly generic entry or competitive displacement?

Competitive displacement by newer classes is typically the larger long-term demand driver once direct generic equivalence is already established.

---

References (APA)

1. FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Accessed 2026). https://www.accessdata.fda.gov/scripts/cder/daf/
2. IQVIA/IMS and industry sales databases (latest annual and quarterly brand reporting). (Accessed 2026).